Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
27.80
-0.01 (-0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
Next >
Analyst Expectations for Genmab's Future
August 15, 2023
Via
Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
12 Analysts Have This to Say About Genmab
July 24, 2023
Via
Benzinga
3 Biotech Stocks That AI is Loving in July
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Where Genmab Stands With Analysts
June 26, 2023
Via
Benzinga
Expert Ratings for Genmab
June 06, 2023
Via
Benzinga
Recap: Genmab Q1 Earnings
May 10, 2023
Via
Benzinga
How To Attend Genmab Q1 2023 Earnings Conference Call
May 08, 2023
Via
Benzinga
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
July 02, 2023
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
Via
The Motley Fool
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
June 28, 2023
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...
Via
Benzinga
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
May 19, 2023
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
Via
Benzinga
Price Over Earnings Overview: Genmab
April 27, 2023
Via
Benzinga
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst
April 24, 2023
Via
Benzinga
Analyst Ratings for Genmab
April 20, 2023
Via
Benzinga
P/E Ratio Insights for Genmab
April 11, 2023
Via
Benzinga
This Foreboding Sign Looms Over Genmab's Chart
March 31, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Genmab
March 01, 2023
Via
Benzinga
Earnings Outlook For Genmab
February 21, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Alkermes Stock Sees Rising Relative Price Strength
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
3 Biotech Companies to Watch in 2023
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
Our 7 Top Biotech Stock Picks for 2023
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.